DOD BIOTECH PUBLIC COMPANY LIMITED



111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000

(Translate)

NO. DOD 030/2019

August 13, 2019

Subject:Clarification of the operating results for the six-month period of 2019, change of rate more than 20 percentDearDirector and Manager

The Stock Exchange of Thailand

According to the resolution of the Board of Directors of DOD Biotech Public Company Limited ("the Company") No. 7/2019 on 13 August 2019, it was resolved to approve the financial statements and the operating results of the Company. For the period ended June 30, 2019, which has been audited by the auditor with significant operational results as follows.

	Consolidated*		Increase /	
(Unit: Baht million)	Quarter 2/2019	Quarter 2/2018	(Decrease)	% Change
Revenues from sales	127.23	233.94	(106.71)	-45.61%
Other revenues	1.17	0.4	0.77	192.50%
Total revenues	128.40	234.34	(105.94)	-45.21%
Cost of sales	56.70	88.41	(31.71)	-35.87%
Selling expenses	8.51	12.23	(3.72)	-30.42%
Administrative expenses	35.24	19.75	15.49	78.43%
Foreign Exchange loss	6.57	-	6.57	100.00%
Finance cost	2.90	0.53	2.37	447.17%
Profit before income tax				
expenses	18.48	113.42	(94.94)	-83.71%
Income tax expenses (revenues)	1.72	1.32	0.4	30.30%
Profit for the year	16.76	112.1	(95.34)	-85.05%
Unrealized gain (loss) from				
valuation	(13.25)	-	(13.25)	100.00%
Income tax relating to components				
of other comprehensive income				
(loss)	2.65	-	2.65	100.00%

DOD BIOTECH PUBLIC COMPANY LIMITED



111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000

	Consolidated*		Increase /	
(Unit: Baht million)	Quarter 2/2019	Quarter 2/2018	(Decrease)	% Change
Total other comprehensive				
income	(10.60)	-	(10.60)	100.00%
Total comprehensive income for				
the year	6.16	112.1	(105.94)	-94.50
Gross profit margin	55.45%	62.21%		-6.76%
Net profit margin	8.26%	47.84%		-39.58%

* Note the financial statements for the 2nd quarter ended Ended 30 June 2019, presented as consolidated financial

statements

1. Revenue from sales

The company has sales revenue in the second quarter of 2019, amounting to 127.23 million baht, decreasing from the same period of the previous year by 106.71 million baht or 45.61 percent. Beauty food supplements in the shape care group.

2. Cost of sales and gross margin

The Company's cost of sales in the second quarter of 2019 was 56.70 million baht, a decrease of 31.71 million baht or 35.87 percent from the same period last year. The gross profit margin in 2019 was 55.45 percent or decreased. Down from the same period of the previous year by 6.76 percent, a decrease in the corresponding cost of sales with the decrease in sales revenue in this period.

3. Selling expenses

The company has selling expenses in the second quarter of 2019 in the amount of 8.51 million baht, decreasing from the same period of the previous year in the amount of 3.72 million baht or 30.42 percent decrease due to the decrease of the commission fee in accordance with the decrease in sales.

4. Administrative expenses

The company had administrative expenses in the second quarter of 2019, amounting to 35.24 million baht, an increase of 15.49 million baht or 78.43% from the same period of last year. PPCA Laboratories Ltd. and Ultima Life Company Limited.

5. Net profit and net profit margin

DOD BIOTECH PUBLIC COMPANY LIMITED



111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000

The Company had total comprehensive income for the second quarter of 2019 amounting to 6.16 million baht, a decrease of 105.94 million baht or 94.50 percent from the same period last year, with a net profit margin of 8.26 percent, a decrease compared to the same period. 39.58% of the previous year due to lower sales and administrative expenses Including loss from exchange rate and unrealized loss from valuation of available-for-sale investments in the amount of Baht 19.82 million.

Financial position

The total assets of the company as of June 30, 2019 amounted to 1,529.83 million baht, an increase of 123.19 million baht or 8.75 percent increase compared with 31 December 2018, with the amount of 1,406.64 million baht due to goodwill from the purchase. PPA Laboratory Co., Ltd., amounting to Baht 108 million. To invest in buying PCA Company Laboratories Co., Ltd. (indirect subsidiary) can produce and sell cosmetics. Which will increase revenue and profit for the company in the future.

The total liabilities of the Company as of June 30, 2019 amounted to 277.54 million baht, a increase of 55.20 million baht or 24.82 percent compared to 31 December 2018, which amounted to 222.34 million baht. Long-term loans from financial institutions in the amount of 66.36 million baht.

The shareholders' equity of the company as of 30 June 2019 amounted to 1,252.29 million baht, an increase of 68.03 million baht or 5.74 percent increase compared to 31 December 2018, which amounted to 1184.26 million baht. Net profit during the six-month period of Baht 68.03 million.

Please be informed accordingly.

Yours sincerely

(Miss Suwarin Konthong)

Director